BioSpace News Archive

Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.

Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.

The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

Day One Biopharmaceuticals announced its fourth quarter and full year 2022 financial results and highlighted recent corporate achievements.

Denovo Biopharma LLC (“Denovo”), a pioneer in applying precision medicine to the development of innovative therapies, set up a gene registry web portal and invites people who suffer from treatment-resistant depression (TRD) to visit www.iMatchDepression.com to help identify whether they or someone they know may be eligible to participate in a biomarker-guided global Phase 2b clinical trial (the “ENLIGHTEN” study).

CTI BioPharma Corp. today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan.

Tabula Rasa HealthCare, Inc.® (Nasdaq: TRHC) (“TRHC” or the “Company”), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the fourth quarter and full year ended December 31, 2022.

vTv Therapeutics Inc. today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments.